vs

Side-by-side financial comparison of Profound Medical Corp. (PROF) and Vivos Therapeutics, Inc. (VVOS). Click either name above to swap in a different company.

Profound Medical Corp. is the larger business by last-quarter revenue ($6.0M vs $3.8M, roughly 1.6× Vivos Therapeutics, Inc.). Profound Medical Corp. runs the higher net margin — -136.8% vs -180.3%, a 43.5% gap on every dollar of revenue.

CompuGroup Medical SE & Co. KGaA is a German publicly listed software company based in Koblenz that develops and offers software for the healthcare sector. It produces cloud-based and digital application software to support medical and organizational activities in doctors' practices, pharmacies, medical laboratories and hospitals. According to its own figures, the company employed more than 9,200 people worldwide in 2022, and has over 1.6 million users in 56 countries. CompuGroup Medical shar...

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

PROF vs VVOS — Head-to-Head

Bigger by revenue
PROF
PROF
1.6× larger
PROF
$6.0M
$3.8M
VVOS
Higher net margin
PROF
PROF
43.5% more per $
PROF
-136.8%
-180.3%
VVOS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PROF
PROF
VVOS
VVOS
Revenue
$6.0M
$3.8M
Net Profit
$-8.2M
$-6.9M
Gross Margin
66.8%
78.1%
Operating Margin
-123.3%
-166.8%
Net Margin
-136.8%
-180.3%
Revenue YoY
3.4%
Net Profit YoY
-143.8%
EPS (diluted)
$0.27
$-0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PROF
PROF
VVOS
VVOS
Q4 25
$6.0M
$3.8M
Q3 25
$5.1M
$6.8M
Q2 25
$2.0M
$3.8M
Q1 25
$2.3M
$3.0M
Q4 24
$3.7M
Q3 24
$3.9M
Q2 24
$4.1M
Q1 24
$3.4M
Net Profit
PROF
PROF
VVOS
VVOS
Q4 25
$-8.2M
$-6.9M
Q3 25
$-8.0M
$-5.4M
Q2 25
$-15.7M
$-5.0M
Q1 25
$-10.7M
$-3.9M
Q4 24
$-2.8M
Q3 24
$-2.6M
Q2 24
$-1.9M
Q1 24
$-3.8M
Gross Margin
PROF
PROF
VVOS
VVOS
Q4 25
66.8%
78.1%
Q3 25
77.7%
58.0%
Q2 25
81.7%
55.2%
Q1 25
79.2%
50.0%
Q4 24
56.7%
Q3 24
60.5%
Q2 24
65.4%
Q1 24
56.7%
Operating Margin
PROF
PROF
VVOS
VVOS
Q4 25
-123.3%
-166.8%
Q3 25
-176.2%
-69.8%
Q2 25
-696.9%
-127.4%
Q1 25
-477.0%
-129.9%
Q4 24
-75.9%
Q3 24
-68.5%
Q2 24
-47.8%
Q1 24
-110.7%
Net Margin
PROF
PROF
VVOS
VVOS
Q4 25
-136.8%
-180.3%
Q3 25
-157.7%
-79.6%
Q2 25
-792.3%
-131.2%
Q1 25
-458.1%
-128.1%
Q4 24
-76.4%
Q3 24
-67.8%
Q2 24
-47.6%
Q1 24
-110.1%
EPS (diluted)
PROF
PROF
VVOS
VVOS
Q4 25
$0.27
$-0.58
Q3 25
$0.26
$-0.49
Q2 25
$0.52
$-0.55
Q1 25
$0.36
$-0.45
Q4 24
$0.41
Q3 24
$-0.40
Q2 24
$-0.60
Q1 24
$-1.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PROF
PROF
VVOS
VVOS
Cash + ST InvestmentsLiquidity on hand
$59.7M
$2.0M
Total DebtLower is stronger
$4.5M
$2.9M
Stockholders' EquityBook value
$66.4M
$-1.5M
Total Assets
$77.5M
$25.2M
Debt / EquityLower = less leverage
0.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PROF
PROF
VVOS
VVOS
Q4 25
$59.7M
$2.0M
Q3 25
$24.8M
$3.1M
Q2 25
$35.2M
$4.4M
Q1 25
$46.4M
$2.3M
Q4 24
$6.3M
Q3 24
$6.3M
Q2 24
$6.9M
Q1 24
$2.6M
Total Debt
PROF
PROF
VVOS
VVOS
Q4 25
$4.5M
$2.9M
Q3 25
$4.5M
Q2 25
$4.5M
Q1 25
$4.5M
Q4 24
$1.2M
Q3 24
$1.2M
Q2 24
$1.2M
Q1 24
Stockholders' Equity
PROF
PROF
VVOS
VVOS
Q4 25
$66.4M
$-1.5M
Q3 25
$32.1M
$2.5M
Q2 25
$39.3M
$4.6M
Q1 25
$50.8M
$4.4M
Q4 24
$8.0M
Q3 24
$7.7M
Q2 24
$6.3M
Q1 24
$582.0K
Total Assets
PROF
PROF
VVOS
VVOS
Q4 25
$77.5M
$25.2M
Q3 25
$42.3M
$25.6M
Q2 25
$49.7M
$26.0M
Q1 25
$60.9M
$11.3M
Q4 24
$15.3M
Q3 24
$15.3M
Q2 24
$15.8M
Q1 24
$11.8M
Debt / Equity
PROF
PROF
VVOS
VVOS
Q4 25
0.07×
Q3 25
0.14×
Q2 25
0.11×
Q1 25
0.09×
Q4 24
0.15×
Q3 24
0.16×
Q2 24
0.19×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PROF
PROF
VVOS
VVOS
Operating Cash FlowLast quarter
$-6.6M
$-3.8M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-139.7%
Capex IntensityCapex / Revenue
40.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-17.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PROF
PROF
VVOS
VVOS
Q4 25
$-6.6M
$-3.8M
Q3 25
$-9.6M
$-4.2M
Q2 25
$-13.7M
$-3.5M
Q1 25
$-8.3M
$-3.8M
Q4 24
$-2.9M
Q3 24
$-4.2M
Q2 24
$-3.0M
Q1 24
$-2.5M
Free Cash Flow
PROF
PROF
VVOS
VVOS
Q4 25
$-5.3M
Q3 25
$-4.2M
Q2 25
$-4.3M
Q1 25
$-3.9M
Q4 24
$-3.1M
Q3 24
$-4.4M
Q2 24
$-3.1M
Q1 24
$-2.7M
FCF Margin
PROF
PROF
VVOS
VVOS
Q4 25
-139.7%
Q3 25
-62.6%
Q2 25
-111.6%
Q1 25
-129.9%
Q4 24
-84.0%
Q3 24
-113.4%
Q2 24
-76.7%
Q1 24
-78.0%
Capex Intensity
PROF
PROF
VVOS
VVOS
Q4 25
40.0%
Q3 25
1.2%
Q2 25
20.2%
Q1 25
4.0%
Q4 24
4.5%
Q3 24
5.0%
Q2 24
1.5%
Q1 24
4.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PROF
PROF

Segment breakdown not available.

VVOS
VVOS

Services$3.2M84%
Products$594.0K16%

Related Comparisons